Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Recruiting · NCT04865887 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-09-10 | NCT04865887 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Georgetown University | 73 |
| Merck Sharp & Dohme LLC | 650 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Georgia Cancer Center at Augusta University | Augusta | United States | 23 |
| John Theurer Cancer Center at Hackensack UMC | Hackensack | United States | 11 |
| MedStar Georgetown University Hospital | Washington D.C. | United States | 204 |
| MedStar Washington Hospital Center | Washington D.C. | United States | 207 |